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Objectives. This study attempted to assess myocardial sympa-
thetic innervation using iodine-123 (I-123) metaiodobenzylguani-
dine (MIBG) imaging in patients with familial amyloid polyneu-
ropathy.
Background. Signs and symptoms of cardiac autonomic dys-
function are commonly seen in patients with cardiac amyloidosis.
However, the incidence and magnitude of abnormalities in myo-
cardial sympathetic nerve function by means of I-123 MIBG
imaging and their relation to clinical findings, cardiac function
and the results of thallium-201 (Tl-201) and technetium-99m
pyrophosphate (Tc-99m PYP) myocardial scanning have not yet
been clarified.
Methods. We performed M-mode, two-dimensional and Dopp-
ler echocardiography and I-123 MIBG, Tl-201 and Tc-99m PYP
imaging of the heart in 12 patients with familial amyloid polyneu-
ropathy and biopsy-proved cardiac amyloidosis.
Results. Ten of 12 patients had no clinical evidence of overt
heart disease, but left ventricular (LV) wall thickening was
observed in 4 of these 10. Left ventricular percent fractional
shortening and Doppler transmitral flow velocity patterns were
found to be normal in all 12 patients. Eight of 12 patients showed
no myocardial MIBG accumulation, with limited uptake in the
remaining 4 demonstrated only in the LV anterior wall. Diffuse
but mild myocardial uptake of Tc-99m PYP occurred in only 4 of
12 patients, and all 12 had normal results on Tl-201 myocardial
scanning. Complete defects on myocardial MIBG scans were
found in five of eight patients with negative findings on Tc-99m
PYP myocardial scanning. The incidence and magnitude of myo-
cardial uptake of MIBG were independent of clinical findings,
extent of endomyocardial amyloid deposition, electrocardio-
graphic QRS voltage and ventricular wall thickness.
Conclusions. Patients with familial amyloid polyneuropathy
show a high incidence of myocardial adrenergic denervation with
viable myocardium that can be identified very early in cardiac
amyloidosis, before the development of clinically apparent heart
disease, ventricular wall thickening, significant LV systolic and
diastolic dysfunction and positive findings on Tc-99m PYP myo-
cardial scanning.
(J Am Coll Cardiol 1997;29:168–74)
q1997 by the American College of Cardiology
Recent studies (1–4) have shown that iodine-123 (I-123)
metaiodobenzylguanidine (MIBG), a radiolabeled analog of
the adrenergic blocking agent guanethidine, is taken up by
myocardial sympathetic nerves and behaves quantitatively sim-
ilar to norepinephrine. Because myocardial accumulation of
MIBG and its relation to myocardial tissue norepinephrine
content have been extensively studied and validated (5,6),
MIBG scintigraphy is widely used to assess cardiac adrenergic
nerve function. Alterations in MIBG concentrations reflect
integrity and function of adrenergic nerves. Decreased cardiac
uptake of MIBG has been identified in diseases or pathologic
conditions in which norepinephrine content or uptake, or both,
is reduced, such as cardiomyopathies (7–10), myocardial in-
farction (11–14), congestive heart failure (8,15,16), generalized
autonomic neuropathies associated with diabetes mellitus (17–
19) and Shy-Drager syndrome (17,20), transplanted heart
(21,22), idiopathic long QT syndrome (23) and neuromuscular
disease (24).
Familial amyloid polyneuropathy is a hereditary systemic
amyloidosis with polyneuropathy that shows chronic progres-
sion and variable degrees of amyloid infiltration into the heart
(25–27). One of the most common symptoms is related to
autonomic dysfunction involving the cardiovascular, gastro-
intestinal and urogenital systems (26,27), and several investi-
gators (28) have demonstrated involvement of the cardiac
autonomic nervous tissues innervating the sinoatrial and atrio-
ventricular (AV) nodes secondary to extensive amyloid depo-
sition. However, there have been no precise reports on myo-
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cardial sympathetic nervous activity in this disorder by I-123
MIBG scintigraphy.
The present study was designed to assess the incidence and
magnitude of abnormalities in myocardial sympathetic nerve
dysfunction by means of I-123 MIBG imaging and to deter-
mine their relation to clinical findings, cardiac function and the
results of myocardial thallium-201 (Tl-201) and technetium-
99m pyrophosphate (Tc-99m PYP) scanning in patients with
familial amyloid polyneuropathy.
Methods
Patients. We studied 12 patients with familial amyloid
polyneuropathy (six men, six women; 17 to 44 years old, mean
[6SD] age 38.3 6 8.1) who were referred to us from several
locations in Nagano Prefecture in the central part of Japan
(26,27). The diagnosis was based on neurologic findings and
pedigrees and confirmed by amyloid deposition in biopsy
specimens obtained from the stomach, rectum, sural nerve or
abdominal fat tissue. Right ventricular (RV) endomyocardial
biopsy was performed in 10 of the 12 patients, and histologic
evidence of amyloid deposition was found in all 10. All patients
had a complete history taken, physical examination and auto-
nomic function tests examining blood pressure response to
standing, heart rate variability at rest using the RR interval
coefficient of variation on the electrocardiograms (ECG) (29)
and plasma norepinephrine levels. They also underwent chest
roentgenographic; ECG;M-mode, two-dimensional andDopp-
ler echocardiographic studies; and I-123 MIBG, Tl-201 and
Tc-99m PYP scintigraphic examinations. No patient had any
other disease, such as diabetes mellitus, that could contribute
to a cardiac adrenergic neuropathy, and none were taking
medications that could interfere with MIBG uptake and
assessment of autonomic function. Correlations between I-123
MIBG scintigraphic findings and the degree of neurologic
disabilities, duration of illness, extent of endomyocardial amy-
loid deposition, ECG QRS voltage, echocardiographic findings
and the results of Tl-201 and Tc-99m PYP myocardial scanning
were then examined. Neurologic disabilities were classified
according to the criteria of Coutinho et al. (30) as follows: stage
I5 peripheral neuropathy limited to the lower limbs; stage II5
neuropathy involving both the lower and upper limbs; and stage
III 5 bedridden because of extensive progressive neuropathy.
In addition, we examined 15 normal volunteers (eight men,
seven women; 24 to 47 years old, mean age 39.8 6 9.3) without
evidence of cardiovascular disease. All had normal findings on
their physical examination, chest roentgenograms and ECGs,
and they served as normal control subjects. They also under-
went autonomic function tests. Written informed consent was
obtained from each subject included in the study.
Echocardiographic examinations. M-mode echocardio-
grams derived from two-dimensional images were obtained,
and the measurements included left ventricular (LV) internal
end-diastolic and end-systolic dimensions and ventricular sep-
tal wall thickness and LV posterior wall thickness at end-
diastole (31). Left ventricular percent fractional shortening
was then calculated. Doppler recordings of transmitral flow
velocity were obtained through an apical four-chamber view
with a Doppler cursor oriented parallel to the long-axis plane
of the LV, and the sample volume was carefully placed at the
tip of the mitral leaflets (32).
Scintigraphic examinations. Iodine-123 MIBG scanning
was carried out within 1 week of the ECG, echocardiographic
and Tl-201 and Tc-99m PYP scintigraphic examinations. The
scintigraphic studies were performed with a scintillation cam-
era (ZLC 7500, Siemens, Solana, Sweden) with a parallel-hole
general-purpose collimator (low energy, high resolution type).
The camera was interfaced to a digital data acquisition system
(Scintipac 2400, Shimazu, Kyoto, Japan). The images were
independently examined by two experienced nuclear cardiolo-
gists (M.T., T.F.) without knowledge of the clinical findings.
Thallium-201 imaging. Three millicuries of Tl-201 chloride
was administered intravenously at rest. Scintigrams were ob-
tained in the anterior, 458 left anterior oblique and left lateral
views 10 min after the injection, and 500,000 counts/view were
acquired. In each Tl-201 study, single-photon emission com-
puted tomography (SPECT) was applied. Thirty-two projec-
tions were acquired over a 1808 arc from right anterior oblique
to left posterior oblique views with 30 s/step. Oblique-angle
myocardial tomograms were reconstructed using a filtered
backprojection algorithm and a Hamming/Hann filter. The
reconstructed tomographic data were displayed in three
planes, including the horizontal long axis, vertical long axis and
short axis. A 20% energy window was centered at 72 and 169
keV.
Iodine-123 MIBG imaging. Four millicuries of I-123 MIBG
was injected as an intravenous bolus with patients in a relaxed
supine position. Scintigrams were obtained in the anterior, 458
left anterior oblique and left lateral views at 30 min (early
images) and 3 h (delayed images) after the injection. A 20%
window centered at 159 keV was used, and 500,000 counts/view
were collected. The SPECT studies were carried out in the
same manner as in the Tl-201 SPECT methods, including the
settings of the cardiac axes.
Technetium-99m PYP imaging. Scintigrams were recorded
3 h after intravenous injection of 20 mCi of Tc-99m PYP. A
20% window centered at 140 keV was used, and 500,000
counts/image were acquired. Four images, including anterior,
458 left anterior oblique, left lateral and 308 right anterior
oblique views, were obtained. The images were graded accord-
Abbreviations and Acronyms
AV 5 atrioventricular
ECG 5 electrocardiogram, electrocardiographic
I-123 MIBG 5 iodine-123 metaiodobenzylguanidine
LV 5 left ventricle, left ventricular
RV 5 right ventricular
SPECT 5 single-photon emission computed tomography
Tc-99m PYP 5 technetium-99m pyrophosphate
Tl-201 5 thallium-201
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ing to level of radioactivity in the cardiac region as follows: 05
negative; 15 faint activity in the heart; 25 definite activity but
less intense than that in the ribs; 3 5 intensity equal to that in
the ribs but less than that in the sternum; and 4 5 intensity
equal to or greater than that in the sternum. Diffuse myocar-
dial uptake of grade$2 were considered positive scans accord-
ing to the criteria of Parkey et al. (33). SPECT studies were
then performed in all patients. The gantry was rotated 1808
around the long-axis of the patient, collecting data from 32
views. These images were reconstructed into 12-mm thick
multiple slices in the transaxial plane (34).
Statistical analysis. Results are expressed as mean value6
standard deviation. The chi-square test was used to compare
the incidence of the variables, and the unpaired t test was
performed to analyze the differences in the results of the
autonomic function tests and ECG QRS voltage. A probability
value ,0.05 was considered statistically significant.
Results
Clinical presentation. All patients had one or more of the
autonomic symptoms, including alternating constipation and
diarrhea, nausea and vomiting, hypotension, impotence, dys-
uria and urinary incontinence, and trophic changes of the skin
and anhydrosis. Patients were classified neurologically as fol-
lows: stage I in five patients; stage II in four; and stage III in
three (Table 1). Duration of the illness from the onset of
symptoms ranged from 1 to 10 years (0 to 5 years in seven
patients, .5 years in five; mean 5.3 6 3.3 years) (Table 1).
Right ventricular endomyocardial amyloid deposition was
found to be mild in 3 of 10 patients, moderate in 6 and severe
in 1 (Table 1). Two patients (Patients 4 and 5) had had a
permanent pacemaker implanted because of Adams-Stokes
syndrome due to severe sinus node dysfunction and complete
AV block, respectively, and the remaining 10 had no clinical
evidence of overt heart disease, such as congestive heart failure
and restrictive cardiomyopathy. Chest roentgenographic exam-
ination revealed cardiac enlargement in none of the 12 pa-
tients. One or more 12-lead ECG abnormalities were present
in eight patients, but low voltage in either limb or precordial
leads (35) was absent in all.
All patients had postural hypotension with a systolic blood
pressure difference .10 mm Hg. The pressure difference in
response to standing was significantly greater in patients than
in normal control subjects (19.76 6.6 vs. 1.36 2.9 mmHg, p,
0.001). The coefficients of variation of the RR interval on the
rest ECG averaged 1.78 6 0.31 in patients 30 to 39 years old
and 1.17 6 0.25 in those 40 to 49 years old, compared with the
coefficients in normal subjects (5.23 6 2.58 for 30 to 39 years
old, p , 0.05, and 4.22 6 1.71 for 40 to 49 years old, p , 0.05).
Basal plasma norepinephrine levels in eight patients in whom
these could be measured were within normal range in all eight.
Echocardiographic findings. Thickened ventricular walls
were present in only 4 (33%) of 12 patients, whereas LV
chamber size, percent fractional shortening and Doppler trans-
mitral flow velocity patterns were normal in all 12 (Table 1).
Myocardial scintigraphic findings. Thallium-201 imaging.
Both plannar and SPECT images showed completely normal
myocardial perfusion in all 12 patients (Table 1).
Technetium-99m PYP imaging. Diffuse positive myocardial
uptake of Tc-99m PYP, which was judged to be mild (grade 2),
was observed in 4 (33%) of 12 patients, whereas scan results
were negative in the remaining 8 (Table 1).
Iodine-123 MIBG imaging. Eight (67%) of 12 patients had
no LV myocardial localization of MIBG on either the early or
delayed images (Fig. 1); the remaining 4 patients showed
myocardial uptake of MIBG in the LV anterior wall only
(Table 1). No patient exhibited RV MIBG uptake. Age,
gender distribution, duration of the illness, neurologic disabil-
ities, ventricular chamber size, ventricular wall thickness, re-
sults of autonomic function tests, basal plasma catecholamine
levels and ECG QRS voltage did not differ significantly
Table 1. Clinical, Echocardiographic and Myocardial Scintigraphic Findings in 12 Patients With Familial Amyloid Polyneuropathy
Pt No./
Gender Age (yr) Disease Stage*
Duration of
Disease (yr)
Endomyocardial
Amyloid
Deposition
VST
(mm)
PWT
(mm)
FS
(%)
TMFV
Pattern
Myocardial Uptake
I-123 MIBG Tl-201 Tc-99m PYP†
1/F 42 II 7 Moderate 8 10 52 Normal 0 Normal 2
2/F 44 I 3 Mild 10 10 40 Normal 0 Normal 1
3/F 42 III 6 Moderate 9 8 50 Normal Anterior Normal 2
4/M 38 II 10 Moderate 10 11 43 Normal Anterior Normal 1
5/M 34 III 4 Severe 14 13 44 Normal 0 Normal 0
6/M 17 I 1 Moderate 10 9 38 Normal Anterior Normal 0
7/M 49 II 12 Moderate 14 12 34 Normal 0 Normal 2
8/F 38 I 0.6 Mild 10 9 38 Normal 0 Normal 1
9/M 39 I 5 Moderate 11 10 40 Normal 0 Normal 1
10/F 34 I 5 Mild 11 10 32 Normal Anterior Normal 0
11/M 36 III 6 NA 13 13 31 Normal 0 Normal 2
12/F 46 II 4 NA 13 12 33 Normal 0 Normal 1
*See Methods for definition of disease stages. †See Methods for explanation of uptake grades. Anterior5 left ventricular anterior wall; FS5 fractional shortening;
I-123 MIBG 5 iodine-123 metaiodobenzylguanidine; NA 5 not available; Pt 5 patient; PWT 5 posterior wall thickness; Tc-99m PYP 5 technetium-99m
pyrophosphate; Tl-201 5 thallium-201; TMFV 5 transmitral flow velocity; VST 5 ventricular septal wall thickness; 0 5 absent.
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between patients with and without absent myocardial uptake of
MIBG. The sum of SV1 1 RV6 in precordial leads in eight
patients with complete defects on myocardial MIBG scans was
28.86 6.5 mm versus 29.66 4.7 mm (p5NS) in the remaining
four patients with limited but positive myocardial uptake of
MIBG. There were no significant differences in the incidence
of myocardial defects on MIBG scans in relation to neurologic
disabilities (three of five patients in neurologic stage I; three of
four in stage II; two of three in stage III), duration of the illness
(five of seven patients with duration 0 to 5 years; three of five
with duration .5 years) and extent of amyloid deposition in
the RV endomyocardium (two of three patients with mild,
three of six with moderate, one of one with severe deposition).
No significant correlations were found between the prevalence
of decreased myocardial uptake of MIBG and ventricular wall
thickness and the results of Tc-99m PYP scanning. Loss of
myocardial uptake of MIBG was found in all patients with
ventricular wall thickening and in four of eight without in-
creased wall thickness. Complete defects on myocardial MIBG
scans were present in five of eight patients with negative
findings on Tc-99m PYP myocardial scanning and in three of
four who showed positive myocardial uptake of PYP (Table 1,
Fig. 1 and 2). Patient 4 (one of the two patients with perma-
nent pacemaker) had limited myocardial uptake of MIBG, and
Patient 5 showed absent myocardial uptake (Table 1).
Clinical course. All patients were followed up for a mean
of 15.5 6 5.8 months (range 9 to 35). No patient died of
cardiovascular disease during the follow-up period. However,
two patients (Patients 3 and 12) developed severe sinus node
dysfunction 5 and 12 months, respectively, after the scinti-
graphic studies and had a permanent pacemaker implanted.
Both patients had shown loss of myocardial uptake of MIBG
(Table 1), but neither developed lethal cardiac arrhythmias,
and clinical and echocardiographic findings in these two pa-
tients were similar to those in the other eight patients without
clinically significant bradyarrhythmias.
Discussion
To our knowledge, the present study is the first to use I-123
MIBG scintigraphy to analyze myocardial sympathetic nervous
activity in patients with familial amyloid polyneuropathy and
biopsy-proved cardiac amyloidosis. Although some of the
bedside autonomic function tests, such as sinus arrhythmia
during deep breathing, reflect cardiac parasympathetic nervous
activity, direct noninvasive methods to assess cardiac sympa-
thetic nervous function are not yet available. The major
advantage of I-123 MIBG myocardial scintigraphy is its ability
to directly and noninvasively assess cardiac adrenergic inner-
vations in specific anatomic regions, which cannot be accom-
plished by the traditional autonomic function tests.
Iodine-123 MIBG scintigraphic findings in patients with
autonomic dysfunction. Several investigators have reported
abnormal myocardial localization and washout of I-123 MIBG
in patients with systemic diseases associated with autonomic
dysfunction or neuropathies. Nakajo et al. (20) found rapid
clearance of MIBG from the heart in patients with severe
autonomic dysfunction compared with that in normal subjects.
Sisson et al. (17) noted little or no myocardial uptake of MIBG
despite normal Tl-201 myocardial perfusion in patients with
autonomic neuropathies due to diabetes mellitus, Shy-Drager
syndrome and unknown origin, which was strikingly different
from the uptake in normal subjects. All patients had severe
autonomic dysfunction assessed by the simple bedside tests.
The other investigators (18,19) pointed out greatly diminished
accumulation of MIBG in the heart of patients with diabetes
Figure 1. Myocardial scintigraphic images from a 42-year old woman
(Patient 2) with biopsy-proved cardiac amyloidosis. A, Short-axis
images with Tl-201 scintigraphy: myocardial perfusion is completely
normal. B, Transaxial images with Tc-99m PYP scanning show diffuse
but faint myocardial uptake (grade 1). C, Both early (1) and delayed
(2) short-axis images with I-123 MIBG scintigraphy demonstrate no
myocardial localization.
Figure 2. Myocardial scintigrams from a 17-year old man (Patient 6)
with biopsy-proved amyloid heart disease. A, Short-axis images with
Tl-201 scintigraphy reveal normal myocardial perfusion. B,Myocardial
uptake is not visualized (grade 0) with transaxial images with Tc-99m
PYP scanning. C, Early (1) and delayed (2) short-axis images with
I-123 MIBG scintigraphy. Myocardial uptake of I-123 MIBG is
observed only at left ventricular anterior wall (arrows) on both the
early and delayed images.
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mellitus and apparent autonomic dysfunction. The results were
consistent with those of a previous postmortem study (36) that
demonstrated reduced concentration of myocardial norepi-
nephrine in these patients. However, the investigators failed to
find strong correlations between the results of clinical assess-
ment of autonomic dysfunction and the magnitude of abnor-
malities in myocardial MIBG uptake (19).
Involvement of cardiac autonomic nervous system in famil-
ial amyloid polyneuropathy. In contrast to other forms of
cardiac amyloidosis, such as primary amyloidosis, in patients
with familial amyloid polyneuropathy, LV systolic function is
generally preserved, and congestive heart failure rarely occurs
until late in the course of the disease (32,37,38). One of the
most important cardiac manifestations in this disease is a high
incidence of cardiac conduction disturbances (39–41). In
general, previous studies have attributed these abnormalities
only to direct amyloid infiltration into the cardiac conduction
system. However, accumulating evidence suggests that cardiac
autonomic denervation is another contributory factor account-
ing for various kinds of conduction disturbances seen in
patients with familial amyloid polyneuropathy. Some investi-
gators (28) demonstrated in an autopsy study that in addition
to the involvement by direct amyloid deposition, autonomic
innervation to the cardiac conduction system was severely
impaired due to marked degeneration of the autonomic nerves
secondary to amyloid infiltration and that these pathologic
changes were most striking at the sinoatrial node and less so at
the AV node. Furthermore, pathologic findings of the conduc-
tion system corresponded well with the ECG conduction
disturbances during life (28).
Myocardial uptake of I-123 MIBG in familial amyloid
polyneuropathy. In the present study, we found complete
defects on MIBG myocardial scans in 8 of 12 patients and
limited uptake in the remaining 4 in association with severe
systemic autonomic dysfunction. The incidence and magnitude
of myocardial accumulation of MIBG were independent of
clinical findings, including neurologic disabilities, duration of
the illness, extent of endomyocardial amyloid deposition, ECG
QRS voltage and ventricular wall thickness. These findings
strongly suggest that cardiac adrenergic denervation due to
autonomic nervous degeneration (28) accounts for alterations
in I-123 MIBG myocardial imaging in patients with familial
amyloid polyneuropathy. The presence of small localized con-
centrations of MIBG in the LV anterior wall in some patients
indicates that myocardial sympathetic innervation is not
equally impaired in this disease.
As we have previously reported (34), Tc-99m PYP scintig-
raphy may have the potential to detect early myocardial
amyloid infiltration in patients with familial amyloid polyneu-
ropathy because positive findings on myocardial pyrophos-
phate scans can be seen even in the absence of identifiable
heart disease, ventricular wall thickening or abnormal LV
systolic function. Most of our patients lacked these clinical
features. Thus, the majority of them were considered to be in
the early stage of cardiac amyloidosis (32,34,37,38), and we
confirmed the ability of Tc-99m PYP scanning to detect early
myocardial amyloid infiltration in some patients. Furthermore,
we demonstrated complete loss or limited uptake of MIBG by
the heart in five of eight patients with negative findings on
Tc-99m PYP scans whose myocardial amyloid deposition was
considered to be mild to moderate. These findings indicate that
myocardial sympathetic denervation may occur in the very
early stages of cardiac amyloidosis in familial amyloid polyneu-
ropathy.
Before the scintigraphic studies, two patients had had a
permanent pacemaker implanted due to the clinically signifi-
cant bradyarrhythmias. During the follow-up period, an addi-
tional two patients developed severe sinus node dysfunction.
Three of these four patients exhibited complete defects on
MIBG myocardial scans, and the remaining patient showed
limited uptake of MIBG. It is not possible to determine from
our results why some patients developed clinically significant
bradyarrhythmias and others did not because we could not find
any differences in the clinical findings and the results of MIBG
scanning between them, and our study was limited to a small
number of patients.
Clinical implications. Cardiac MIBG scintigraphy has
been reported (42) to have prognostic value in patients with
congestive heart failure compared with other noninvasive
hemodynamic indexes. In addition, a high prevalence of myo-
cardial sympathetic denervation has been described (43) in
patients with ventricular tachycardia in the absence of coro-
nary artery disease. Although clinically significant ventricular
arrhythmias are not common in patients with familial amyloid
polyneuropathy (39–41), some investigators (44) have pointed
out an association between complex ventricular arrhythmias
and cardiac death in patients with primary amyloidosis. Thus,
further investigation is required to assess the role of adrenergic
denervation in the development of complex ventricular ar-
rhythmias and the exact prognostic significance of MIBG
scanning in other forms of cardiac amyloidosis, such as primary
amyloidosis.
Recent reports (45,46) suggest that liver transplantation is
becoming a new promising therapeutic approach in patients
with familial amyloid polyneuropathy because clinical findings,
including neuropathic and autonomic symptoms, generally
improve or do not progress after transplantation. This accom-
panies a decrease in plasma amyloid protein, a variant trans-
thyretin, which is known to be produced in the liver (45,46).
However, there have been no reports on the effects of liver
transplantation on the cardiac autonomic nervous system.
Therefore, it is of great interest to examine whether myocar-
dial sympathetic reinnervation may occur in this disease.
Study limitations. There were several limitations to our
study. The incidence and magnitude of myocardial uptake of
MIBG were not correlated with clinical findings, especially
with the results of the autonomic function tests. However,
basal plasma norepinephrine levels, which we measured, are
generally insensitive indicators of adrenergic dysfunction, and
stimulated levels, obtained by patients standing up, would have
been more sensitive. Therefore, a better relation between
assessment of autonomic dysfunction and the results of MIBG
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imaging might have been obtained if we had performed more
comprehensive autonomic function tests, such as examining
changes in the RR interval in response to the Valsalva
maneuver, deep breathing, standing and sustained hand grip
(29,47). Another consideration was related to the dose and
activity of MIBG. However, we used a standard method of
MIBG scanning, including a dose of MIBG, and the normal
subjects who underwent MIBG scanning on the same day
showed uniform uptake in the heart. Thus, the dose and
activity of MIBG were considered to be appropriate in the
present study.
Conclusions. We assessed myocardial sympathetic innerva-
tion using I-123 MIBG imaging and its relation to clinical
findings, cardiac function and the results of Tl-201 and Tc-99m
PYP myocardial scanning in 12 patients with familial amyloid
polyneuropathy. Ten of 12 patients had no clinical evidence of
overt heart disease and normal ventricular wall thickness, and
all 10 showed normal LV systolic and diastolic function, as well
as normal Tl-201 myocardial perfusion. Eight of 12 of the
patients had absence of myocardial MIBG accumulation, and
the remaining 4 showed limited uptake; only 4 of 12 patients
exhibited diffuse but mild myocardial uptake of Tc-99m PYP.
Complete defects on myocardial MIBG scans were found in 5
of 8 patients with negative findings on Tc-99m PYP myocardial
scanning. The incidence and magnitude of myocardial uptake
of MIBG were not correlated with clinical findings, extent of
endomyocardial amyloid deposition, ECG QRS voltage and
ventricular wall thickness. Thus, patients with familial amyloid
polyneuropathy show a high incidence of cardiac adrenergic
denervation with viable myocardium that can be identified very
early in cardiac amyloidosis.
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